PARP inhibition with olaparib plus antihormonal therapy with abiraterone resulted in significantly prolonged radiologic progression-free survival (rPFS) compared with abiraterone alone among patients with metastatic castration-resistant prostate cancer (mCRPC).
Treatment with docetaxel without prednisone failed to improve biochemical disease-free survival (DFS) compared with surveillance in patients who had undergone radical prostatectomy with androgen deprivation therapy for intermediate- or high-risk prostate cancer.
A high dose of a proton-pump inhibitor (PPI) combined with low-dose aspirin reduced the risk of death, esophageal adenocarcinoma (EA), or high-grade dysplasia (HGD) in patients with Barrett’s esophagus (BE) in a long-term, phase III randomized trial.
The combination of temozolomide and capecitabine resulted in improved progression-free and overall survival (Abstract 4004) compared with temozolomide monotherapy in patients with advanced pancreatic neuroendocrine tumors (NETs).
Neoadjuvant chemoradiotherapy resulted in improved outcomes compared with immediate surgery in patients with resectable and borderline resectable pancreatic cancer, according to results of the phase III PREOPANC trial (Abstract LBA4002).
Adjuvant chemotherapy with a modified FOLFIRINOX (mFOLFIRINOX) regimen was superior to gemcitabine with regard to disease-free, metastasis-free, and overall survival (OS) in patients with resected pancreatic cancer, according to a new randomized phase III trial.
The addition of oxaliplatin hyperthermic peritoneal chemotherapy (HIPEC) combined with cytoreductive surgery in patients with colorectal peritoneal carcinomatosis does not improve overall survival (OS) or recurrence-free survival (RFS).
Using adjuvant denosumab in an intense dosing schedule did not improve bone metastasis–free survival (BMFS) in patients with early-stage breast cancer who were receiving optimal locoregional and standard-of-care systemic adjuvant therapy, according to results from the D-CARE study.
A 6-month duration of adjuvant trastuzumab with chemotherapy was found to be noninferior to 12 months with chemotherapy, which is currently the standard of care, in Persephone, a phase III randomized clinical trial of women with HER2-positive early-stage breast cancer.
Sunitinib alone was not inferior to cytoreductive nephrectomy (CN) followed by sunitinib with regard to overall survival in a phase III trial of patients with intermediate- and poor-risk metastatic renal cell carcinoma (RCC).
Endocrine therapy (ET) alone was noninferior to ET plus chemotherapy for women with estrogen receptor (ER)−positive, HER2-negative, axillary node−negative, early-stage breast cancer (BC) with a midrange score as measured by the Oncotype DX Breast Recurrence Score gene expression assay.
Sorafenib resulted in significantly improved progression-free survival (PFS) compared with placebo in patients with desmoid tumors (DTs) or aggressive fibromatosis, according to results of a randomized phase III trial presented on June 4 (Abstract 11500).
Poster Sessions on June 4 gave an in-depth look at data from the KEYNOTE-183 and KEYNOTE-185 trials, which were halted nearly a year ago due to increased risk of death for patients with multiple myeloma who were being treated with the drug combination.